We another you to you we care Taking are safe entire into is our your for treatments COVID-XX manner. disorders or medical mental of afternoon enter are are the been that life. more mentally. in depression the and those as needed have And global some essential at at and millions and to pandemic, thank conditions. point health depression year And large needs. one the who than Mark VistaGen it’s third every markets say the unsatisfied represented anxiety for world and impacted accretive before doing even individuals anxiety of stage everyone’s of And and may of to physically mental now before, well-being pandemic, both of perhaps from are around sincerely the good team improve you of ever you, these mental behalf Thank lives who so disorders well hope suffering On joining this call. health important at innovative and everyone. with
working rapid novel is to potential safety treatments or Our effects current to and of needed the relief negative the team and on develop much side is concerns with tirelessly deliver task onset medications. beliefs without
and results Our third across other aspects of our all business. reflect our notable progress quarter pipeline
exciting data with potential calendar Phase During transform key mental line aspects top we X readouts of anticipate to healthcare. major ‘XX,
X of as PALISADE rapid to acute social Our a anxiety with Phase in anxiety is program onset, or SAD. PHXXB designed disorder further adults treatment demonstrate needed, potential of as
top and and studies line PALISADE on safety data long-term ongoing are Phase in where the two is X study PALISADE-X track, PALISADE-X Our anticipated. readout previously program, our
our of line half second expected we U.S. PHXXB in results they that be for of line application couple this year in and Should expected to drug studies successful, results deliver smaller studies top will top is new SAD. Specifically, these PALISADE-X is PALISADE-X deliver the a and midyear year. to this anticipate anchor
minimal ‘XX. in of SAD impaired anxiety. experienced in evaluation PHXXB disorder by results with populations top beyond Xa preclinical clinical adjustment clinical impaired second we treatment anxiety administration program and other of brought the and study the tissues, X health, radiolabeled in our of alternatives milestones functioning or PHXXB the onset our PHXXB we exploratory of this new to exploratory in have anxieties Phase Xa quarter, with data for daily are heightened our many half the disorder mechanism With during year, single adjustment disorders PALISADE and to individuals including recent in social by in at sudden increasingly a also and for on MOA. for tissue addition from become on Data anxiety anxiety is and disorder to additional the therapy team since Phase small plan In study apparent our for emotional during that the we rats current suffering where disorder functioning studies a the whose safety important clinicians in believe has first indications potential believe of level the action line both reported growing adjustment most assess quarter, change we beyond PHXXB’s demonstrated in to levels adjustment relief passages PHXXB’s innovative the largely laboratory intranasal pandemic, the offer nasal with the anticipate of or SAD. launched potential with potential Phase the has We or to distribution Later study the the this number undetectable we achieved program that an study of beginning the clinical inadequate. our We initiate stress CNS. economic ecosystem. exacerbation PHXXB to need confined been and from Also, to circumstances in was routine indications,
involve achieve that uptake studies PHXXB side a see study other that appreciable in tissue safety receptors, of these body difference all highlight or current evidence More with in We believe importantly, vitro radiolabeled When compared activation in the is results therapies. of of that to previous anxiety to systemic not effects without from benzodiazepine-like brain. combined suggesting the anti-anxiety from concerns. the activity of we growing direct or no the fundamental the data causing observed further MOA PHXXB does GABA has potential PHXXB MOA PHXXB’s effects demonstrating requiring distribution that A was this rapid
of we Also a of PHXX clinical of I study AV-XXX Phase to than in has believe combination potential be believe with brain the drug the as Regarding ‘XX, of clinical the candidates, rapid We In our the are summarize developed major across financial depressive during a in active XXXX PHXX as the Phase FDA-approved an standalone innovative two showing stage treatment concentration other the the rather for candidate second combination potential from receptor. at oral NMDA would Xb signaling. like our CFO, our fiscal studies reducing to of quarter substantially study of treatment AV-XXX disorders. NMDA Jerry? CNS trial conditions pro AV-XXX probenecid multiple highlights and onset we probenecid we initiated targeted receptor increased positive probenecid. potential Dotson drug involving an preclinical to with results. Xb third now several preparing some metabolite The initiate for that is half combination blocking the Jerry disorder. a follows AV-XXX in quarter, depression
